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REVIEW
Abstract: Hypertension is the most important cardiovascular risk factor for stroke. Blood
pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of
stroke (both primary and secondary), although no clear differences have yet been observed
between antihypertensive drug classes. However, a recent study reported the clear superiority
of the angiotensin-receptor blocker eprosartan over the calcium channel blocker nitrendipine
in cardiovascular protection of hypertensive patients with a previous stroke. Comparative studies
using angiotensin-receptor blockers have also suggested the superiority of this class of drugs
on primary stroke prevention. This effect may be linked to their beneficial actions on left
ventricular hypertrophy, atrial enlargement, and supraventricular arrhythmias, endothelial
dysfunction, inflammation, and remodelling, as well as a direct neuroprotective effect mediated
through the stimulation of the angiotensin II type-2 receptor. In addition, a sympathoinhibition
observed with the renin–angiotensin system blockers and particularly demonstrated with
eprosartan, may help to explain the better cardiovascular and cerebrovascular protection in
comparison with the calcium antagonist nitrendipine.
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Introduction
Cardiovascular disease is the leading cause of death and disability in developed
countries and arterial hypertension is one of the most powerful risk factors for
developing such cardiovascular complications (Lewington 2002). The prevalence of
hypertension is increasing and reaches more than 50% in people aged over 60 (Wolf-
Maier et al 2003). The residual life-time risk for developing hypertension is higher
than 90% (Vasan et al 2002).
The pathogenesis and pathophysiology of essential hypertension is complex and
involves both genetic and environmental aspects. However, it has become clear that
both the renin–angiotensin system (RAS) and the sympathetic nervous system (SNS)
play important roles in the development and maintenance of elevated blood pressure
(BP) values and in the pathogenesis of target organ damage. Bearing this pathogenetic
complexity in mind, therapeutic approaches for hypertension and cardiovascular
diseases include the use of various, very different drug classes, including diuretics,
beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE)
inhibitors, and angiotensin-receptor blockers (ARB) (Chobanian et al 2003; GC 2003).
Angiotensin-receptor blockers selectively antagonize the angiotensin II type 1
(AT1) receptor and counteract most of the deleterious actions of angiotensin II.
Eprosartan is an ARB with a special chemical structure that may be relevant to its
mechanism of action. The pharmacological properties and clinical efficacy and safety
of eprosartan have been previously reviewed (Plosker and Foster 2000; Robins and
Scott 2005).
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In June 2005, an important study reported the superiority
of eprosartan over the calcium channel blocker nitrendipine
in cardiovascular protection of hypertensive patients with a
previous stroke (Schrader et al 2005). The present paper
reviews the main findings of this trial and tries to answer
some questions posed after its publication. The importance
of stroke prevention by ARB in general and eprosartan in
particular are also discussed.
The importance of stroke and the
MOSES study
Stroke is the most frequent cardiovascular complication in
hypertensive patients older than 60. A retrospective analysis
of clinical trials in hypertensive patients published from 1991
to 2000 that included 59 550 randomized patients revealed
that the total number of strokes (2533 events; 4.25%) clearly
exceeded coronary events (1927 events; 3.24%) (Kjeldsen
et al 2001). Blood pressure reduction and control is
extremely important to prevent both stroke appearance
(Collins et al 1990; Staessen et al 2000) and recurrence
(PROGRESS 2000). Comparative trials and meta-analyses
suggest that among different antihypertensive treatments,
calcium channel blockers seem to represent the most
powerful option for stroke prevention (Turnbull 2003; Angeli
et al 2004).
No comparative trials between different antihypertensive
drug classes were reported before the Morbidity and
Mortality after Stroke, Eprosartan compared with
Nitrendipine for Secondary Prevention (MOSES) study. The
MOSES investigators hypothesized that for the same BP
reduction, the ARB eprosartan would be superior to the
calcium channel blocker nitrendipine in the cardiovascular
protection of hypertensive patients with a previous stroke.
Nitrendipine was chosen as a comparative drug on the basis
of the cardiovascular and cerebrovascular protection
observed in two trials of patients with isolated systolic
hypertension (Staessen et al 1997; Wang et al 2000) and, as
mentioned above, due to the fact that calcium channel
blockers seem to be more protective against stroke than other
antihypertensive drug classes.
A total of 1405 patients with a previous cerebrovascular
event (ischemic stroke, transitory ischemic attack, or cerebral
hemorrhage) who were hypertensive (by both clinical
measurements and ambulatory BP monitoring) were
randomized to receive eprosartan 600 mg once daily or
nitrendipine 10 mg once daily. Higher doses or combination
therapy (excluding ARB and calcium channel blockers) were
used in order to achieve a target BP lower than 140/90 mmHg.
The primary endpoint was the composite of total mortality
and all cardiovascular and cerebrovascular events, including
all recurrent events.
The principal results of the MOSES trial revealed the
superiority of eprosartan over nitrendipine in the primary
endpoint (Figure 1). There were 206 primary endpoints in
the eprosartan group (incidence density per 100 person-years
[ID] of 13.25) and 255 primary endpoints in the nitrendipine
group (ID 16.71). The risk reduction for eprosartan was 21%
with confidence limits of 4% to 34% (p = 0.014). Separate
analysis of the different components of the primary endpoint
also revealed a superiority of eprosartan over nitrendipine
in the total number of cerebrovascular events, including
recurrent events (relative risk reduction of 25% with
confidence limits between 3% and 42%; p = 0.026) and,
although nonsignificant, in the total number of cardio-
vascular events, including recurrent events (relative risk
reduction of 25%; p = 0.061).
In addition to the analysis of the total number of events
occurred, MOSES investigators also analyzed the first
occurrence of events in each category. There were no
significant differences between eprosartan and nitrendipine
in the first-time occurrence of cerebrovascular events and
death from any cause, but, once more, eprosartan was
superior to nitrendipine in the prevention of the first
cardiovascular event (risk reduction of 31% with confidence
limits between 3% and 50%; p = 0.031). This better
protection was essentially due to fewer myocardial
infarctions and new cases of heart failure.
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Figure 1 Effect of eprosartan compared with nitrendipine in various endpoints
in the MOSES study.
Abbreviations: CI, confidence interval; MOSES, Morbidity and Mortality after
Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention study.Vascular Health and Risk Management 2006:2(1) 81
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Reasons for better cardiovascular
protection in hypertensive stroke
patients
Evidence-based medicine has demonstrated a superior effect
of eprosartan over nitrendipine on cardiovascular protection.
This is proven, although the explanation remains speculative.
Some of the reasons for this superiority may be linked to a
theoretical class effect of ARB, which have demonstrated a
good profile in both the primary prevention of stroke and
their impact on several risk factors that are clearly implicated
in stroke development and recurrence (Sierra and de la Sierra
2005). However, before exploring these reasons, the effects
of differences in BP or a negative effect of nitrendipine,
which might also have influenced the results, should be ruled
out. The MOSES investigators reported that the effect of
two treatment regimens on BP values were essentially the
same, as were the number of patients reaching BP goals at
both 3 months of treatment and at the end of follow-up.
Moreover, the number of patients receiving combination
therapy and the median number of drugs in each group were
also the same.
With respect to a possible negative effect of nitrendipine
on cerebrovascular protection in patients with a previous
stroke, there are no reports on the effect of calcium channel
blockers on secondary stroke prevention. However, as
mentioned above, recent meta-analyses of comparative trials
of antihypertensive agents found a superior effect of calcium
channel blockers on primary stroke prevention (Turnbull
2003; Angeli et al 2004), while nitrendipine was the basis
of active treatment in patients with isolated systolic
hypertension demonstrating a clear benefit on stroke
prevention (Staessen et al 1997; Wang et al 2000). Thus, it
would not be reasonable to suppose that a drug with a proven
benefit on primary prevention would not have the same
beneficial properties on secondary prevention of the same
cardiovascular event.
The MOSES design was not able to completely rule-out
a possible effect of the add-on therapy on the outcome. As
this add-on therapy was left to the discretion of each
investigator, the type of added medications was not identical
between groups. In fact, although diuretics and beta-blockers
were similarly distributed, more patients in the eprosartan
group received other calcium channel blockers (14.4%
versus 7.5% in the nitrendipine group) whereas ACE
inhibitors were less frequently used (11.3% versus 21% in
the nitrendipine group). Although it seems difficult to
attribute to this imbalance an important role in the
differences in cardiovascular protection observed in the
MOSES trial, a contribution to the differences cannot be
discarded.
ARB and stroke prevention
Three studies have compared ARB with other types of
antihypertensive therapy in primary stroke prevention. The
Losartan Intervention For Endpoint reduction (LIFE) study
(Dahlöf et al 2002) compared losartan and atenolol in
hypertensive patients older than 55 who had electro-
cardiographically detected left ventricular hypertrophy.
Losartan significantly reduced the total number of
cardiovascular events (13%) with minimal differences in
BP changes between treatments. The benefit of losartan was
mainly due to a decrease in the rate of stroke (25% reduction;
p = 0.001).
The Study on Cognition and Prognosis in the Elderly
(SCOPE) included hypertensive patients aged 70–89 who
were randomly assigned to candesartan or placebo with
open-label active antihypertensive treatment added as
needed (Lithell et al 2003). The primary composite endpoint,
a combination of cardiovascular death, stroke, and
myocardial infarction was reduced by 10.9%, which did not
reach statistical significance. Of all the components of the
primary endpoint, only the reduction in non-fatal stroke
(27.8%; 95% confidence interval [CI]: 1.3–47.2; p = 0.04)
was statistically significant. However, there were marked
differences in BP reduction (3.2/1.6 mmHg) between
candesartan and placebo-treated patients.
Finally, the largest study with ARB in hypertensive
patients was the Valsartan Antihypertensive Long-term Use
Evaluation (VALUE) trial. The VALUE trial (Julius et al 2004)
compared two active antihypertensive treatments (valsartan
and amlodipine) in high-risk hypertensives older than 50
years. At the end of the study there were no differences in
the primary endpoint, which occurred in 10.6% of valsartan-
treated patients and in 10.4% of amlodipine-treated patients.
Some of the prespecified secondary endpoints were
favourable to amlodipine with respect to valsartan, including
myocardial infarction and stroke, whereas valsartan slightly
reduced the development of heart failure.
The VALUE trial showed important differences in the
BP reduction achieved by the two treatment regimens. Blood
pressure differences were especially apparent during the first
part of the study (4/2.1 mmHg in the first month) and were
maintained at more than 1mmHg in favour of amlodipine
during the entire follow-up.
Therefore, two of the three above-mentioned trials of
ARB in hypertensive patients suggested a protective effectVascular Health and Risk Management 2006:2(1) 82
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of these drugs in the primary prevention of stroke. In fact,
the cardiovascular protection observed in the LIFE trial was
almost entirely due to stroke prevention. Moreover, although
the primary-endpoint results of the SCOPE trial were not
significant, the rate of non-fatal stroke was lower in the
candesartan group. These results, combined with the
MOSES results with eprosartan, suggest better cerebro-
vascular protection in hypertensive patients treated with
ARB.
Another complementary evidence of a protective effect
of ARB in cerebrovascular prevention comes from the Acute
Candesartan Cilexetil Therapy in Stroke Survivors
(ACCESS) study (Schrader et al 2003). Hypertensive
patients with an acute ischemic stroke were randomized to
early candesartan or placebo, although all except two
patients in the placebo group were then treated with
candesartan 7 days after the stroke. Treatment was
maintained during 12 months. The ACCESS trial
demonstrated a beneficial effect of early candesartan on
mortality (2.9% versus 7.2%; p = 0.07) and in the number
of vascular events (9.8% versus 18.7%; p = 0.026), without
significant differences in the level of BP between groups.
Possible mechanisms of cerebrovascular
protection with ARB
Several different (and probably complementary) mecha-
nisms have been proposed to explain the better
cerebrovascular outcome in patients treated with ARB,
including left ventricular hypertrophy regression, protection
against atrial enlargement and supraventricular arrhythmias,
effects on endothelial function, risk biomarkers and vascular
remodelling, and a specific neuroprotection mediated
through angiotensin II and the angiotensin II type 2 (AT2)
receptor.
In the LIFE trial, the cardiovascular protection observed
was related to left ventricular hypertrophy regression
(Devereux et al 2004; Okin et al 2004). Patients in whom
both the Cornell product and Sokolow-Lyon voltage, (the
electrocardiographic criteria used to define left ventricular
hypertrophy), were reduced exhibited lower rates of the
primary composite endpoint (strokes, myocardial infarctions
and cardiovascular deaths). This included between 10% and
20% reduction in stroke rates (Okin et al 2004). Losartan-
induced changes in these parameters were significantly more
pronounced than those observed in atenolol-treated patients.
These data have been confirmed in the substudy of LIFE in
patients with left ventricular hypertrophy assessed by
echocardiography. In this substudy, left ventricular mass
regression was accompanied by a 24% risk reduction in the
rate of stroke (Devereux et al 2004). This effect on the
regression of left ventricular hypertrophy can also be linked
to better protection against atrial fibrillation. Supra-
ventricular arrhythmias are frequent in hypertensive patients
with diastolic dysfunction related to the increase in
ventricular mass, which promotes atrial enlargement. It is
recognized that atrial fibrillation is one of the main risk
factors for stroke, especially when accompanied by
hypertension, older age, or left ventricular dysfunction. A
post-hoc analysis of the LIFE trial revealed that rates of
new onset atrial fibrillation were significantly reduced in
losartan-treated patients compared with those who received
atenolol (Wachtell et al 2005). This suggests a specific effect
of this class of drugs on myocardium that is not dependent
on BP. Moreover, experimental data show that ARB can
have a direct effect on atrial electrical remodelling
(Nakashima et al 2000). Although differences in new onset
atrial fibrillation in the LIFE trial were too small to account
for stroke differences, these effects of ARB on left
ventricular hypertrophy regression and probably a better
protection against arrhythmias represent advantages in terms
of general cardiovascular protection, including stroke.
Endothelial dysfunction is one of the most important
mechanisms involved in the development of atherosclerosis
and is present in patients with various cardiovascular risk
factors, including hypertension, hypercholesterolemia, and
type 2 diabetes, as well as in patients with coronary artery
disease. Endothelial dysfunction has important prognostic
implications in these groups of patients (Schächinger et al
2000; Perticone et al 2001). Blocking RAS with ARB clearly
ameliorates endothelial dysfunction, an effect that is not
totally dependent on BP reduction. In an elegant study
(Schiffrin et al 2000), resistance arteries obtained from
gluteus subcutaneous biopsies from a small group of
hypertensive patients and normotensive controls were
studied by measuring the endothelium-dependent and
independent responses and the cross-sectional area. Patients
were then randomized to losartan or atenolol for one year
and the procedures repeated. The results showed that patients
treated with losartan normalized acetylcholine-dependent
vasorelaxation and also reduced the ratio of the media/lumen
diameter. No changes were observed in atenolol-treated
patients despite a similar reduction in BP.
The effect of treatment on atherosclerosis biomarkers is
closely linked to endothelial function. Several of these
biomarkers, including acute-phase reactants such as
C-reactive protein and adhesion molecules and selectins thatVascular Health and Risk Management 2006:2(1) 83
Eprosartan and organ protection
mediate vascular inflammation, have been implicated in the
prognosis of patients at risk or those with cardiovascular
diseases, especially coronary artery disease (Blankenberg
et al 2001; Libby et al 2002). Various studies have shown
an improvement in these parameters by blocking the effects
of angiotensin II. Two months of candesartan therapy
promoted reductions in oxidative stress (malondialdehyde),
inflammatory biomarkers (monocyte chemotactic protein,
tumor necrosis factor-α), and thrombotic factors
(plasminogen activator inhibitor type-1) in 45 hypertensive
patients independently of BP changes (Kon et al 2003).
Moreover, C-reactive protein, interleukin-6, and monocyte
chemotactic protein-1 (MCP-1) were reduced in patients
after olmesartan treatment (Fliser et al 2004), while, in the
only comparative study of eprosartan against hydro-
chlorothiazide (Rahman et al 2002), decreases in MCP-1,
soluble vascular cell adhesion molecule-1 (sVCAM-1), and
superoxide anion generation were only observed in patients
treated with eprosartan despite similar BP reductions.
There is growing experimental evidence suggesting that
some actions directly related to the stimulation of the AT2
receptor may be involved in the cerebroprotection of ARB.
Several angiotensin receptors mediate angiotensin II actions.
Most of the deleterious effects of angiotensin II are mediated
by the AT1 receptor, which is selectively blocked by ARB.
Conversely, stimulation of the AT2 receptor by the same
angiotensin II seems to promote vasodilation, natriuresis
and apoptosis and impairs cellular hyperplasia (Fournier et
al 2004). Some preliminary data support the idea that the
AT2 receptor is expressed more intensively in the brain than
in the heart and that this expression is enhanced in patients
with target organ damage, especially when cerebral ischemia
occurs (De Gasparo et al 2000). In experimental models,
AT2 receptor stimulation protects brain tissue from ischemia
(Li et al 2005). Treatment with ARB would increase
angiotensin II concentration (Struck et al 2002), thus
promoting the availability of this angiotensin II to bind the
AT2 receptor and to mediate the previously-mentioned
beneficial actions. Other forms of RAS blockade, such as
treatment with ACE inhibitors, would decrease angiotensin
II and thus would not share the beneficial effects mediated
through AT2 receptor stimulation.
Eprosartan: an ARB with a dual
mechanism of action
In addition to the RAS, the SNS seems to play an important
role in the pathogenesis of essential hypertension, metabolic
syndrome, and target organ damage related to elevated BP.
Sympathoinhibitors, such as moxonidine, peripheral alpha-
blockers, or beta-blockers have been widely used to treat
high BP. In addition, it has been shown that blocking the
RAS with ACE inhibitors or ARB decreases SNS activity
in hypertensive and renal patients (Ligtenberg et al 1999;
Struck et al 2002; Klein et al 2003). In fact, Struck et al
(2002) have demonstrated a clear inhibition of SNS by
valsartan, but not nitrendipine. These results may help to
explain the BP-independent cardiovascular protective effects
of the ARB.
Angiotensin II type 1 receptors located postjunctionally
in the vascular bed promote vasoconstriction, whereas those
located prejunctionally increase norepinephrine outflow to
the junctional area, thus contributing to further vaso-
constriction. Studies in animal models have also shown that
ARB suppress angiotensin II-induced sympathetic outflow,
with differences in affinity for AT1 receptor sites evident
between individual agents within this drug class (Ohlstein
et al 1997; Balt et al 2001; Guimaraes et al 2001). The effect
of eprosartan, candesartan, valsartan, and embusartan on
presynaptically- and postsynaptically-located AT1 receptors
was investigated in the pithed rat model. Whereas the effect
on postsynaptic receptors was dose-dependent for all ARB,
the sympathoinhibitory potency was clearly superior for
eprosartan compared with the other ARB (Balt et al 2001).
Moreover, another study comparing eprosartan and losartan
on both sympathoinhibitor and direct contractile responses
in the canine pulmonary artery (Guimaraes et al 2001) found
a parallel effect of both eprosartan and losartan on direct
contractile responses induced by angiotensin II, whereas at
the prejunctional level, while eprosartan antagonized the
facilitatory effect on noradrenaline release at the same doses
that were effective postjunctionally, losartan was ineffective
even at concentrations 10 times higher than those used to
block the receptor postjunctionally.
These results have been recently confirmed in humans.
In a comparative study against valsartan, eprosartan
significantly reduced several hemodynamic parameters
obtained after adrenergic and noradrenergic stress (Arosio
et al 2005).
Effects of eprosartan on vasculature
Eprosartan is able to reduce several markers of vascular
pathology in both experimental animal models and humans.
In stroke-prone spontaneously hypertensive rats (SHR-SP)
fed with a high-fat, high-salt diet, low doses of eprosartan
(30 mg/Kg/day) induced a significant decrease in myocardial
proinflammatory chemokine MCP-1 expression (Behr et alVascular Health and Risk Management 2006:2(1) 84
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2004). This effect was accompanied by reduced morbidity
and mortality. In a previous study by the same group, SHR-
SP treated with higher doses of eprosartan (60 mg/Kg/day)
showed no mortality at 18 weeks, whereas all those treated
with vehicle died by week 9 (Barone et al 2001).
Studies performed in hypertensive patients have
consistently shown a significant effect of eprosartan on
several markers of vascular damage and dysfunction. In a
non-comparative study of 30 hypertensive patients,
eprosartan significantly reduced platelet activation and
platelet calcium mobilization from baseline (Labios et al
2004). In two comparative studies against losartan (Makris
et al 2004) or enalapril (Leu et al 2004), eprosartan
favourably influenced several markers of coagulation/
fibrinolysis (reduction in plasminogen activator inhibitor-1
[PAI-1] and increase in tissue plasminogen activator [tPA]
antigen), platelet activation, and endothelial function. These
effects were comparable between eprosartan and enalapril,
but superior to losartan. Finally, as mentioned above, in a
comparative study against hydrochlorothiazide, eprosartan
significantly reduced superoxide generation, MCP-1 and
VCAM-1, despite a similar BP reduction (Rahman et al
2001).
Clinical profile of eprosartan
The clinical efficacy of eprosartan has been evaluated in
randomized trials. Eprosartan has been compared with ACE
inhibitors and other ARB (for reviews see Plosker and Foster
2000; Robins and Scott 2005). In patients with mild-to-
moderate hypertension, eprosartan has been demonstrated
to be equally effective compared with enalapril (Elliott 1999;
Ruilope et al 2001). However, in a study that included
patients with severe hypertension, eprosartan was
significantly more effective than enalapril in reducing
systolic BP (–29.1 versus –21.1; p < 0.05) (Sega 1999).
Moreover, in comparative studies against losartan (Garcia
Puig et al 1999) or telmisartan (De Rosa et al 2004), no
differences were observed in BP reduction.
Conclusion
The ARB eprosartan has been shown to be superior to the
calcium channel blocker nitrendipine in preventing
cardiovascular disease in hypertensive stroke patients.
Angiotensin-receptor blockers are able to favourably affect
left ventricular hypertrophy regression, endothelial function,
and markers of vascular inflammation and remodelling, as
well as exert beneficial actions on sympathetic nervous
activity and on brain tissue through the stimulation of the
AT2 receptor. All these actions help to explain the better
outcome observed in the comparison between eprosartan
and nitrendipine in hypertensive stroke patients.
Disclosure
Dr de la Sierra has received honoraria from Solvay
Pharmaceuticals for speaker’s presentations.
References
Angeli F, Verdecchia P, Reboldi GP, et al. 2004. Calcium channel blockade
to prevent stroke in hypertension: a meta-analysis of 13 studies with
103,793 subjects. Am J Hypertens, 17:817–22.
Arosio E, De Marchi S, Prior M, et al. 2005. Haemodynamic effects of
eprosartan and valsartan in hypertensive patients during isometric and
mental stress. J Hypertens, 23:1923–7.
Balt J, Mathy MJ, Pfaffendorf M, et al. 2001. Inhibition of facilitation of
sympathetic neurotransmission and angiotensin II-induced pressor
effects in the pithed rat: comparison between valsartan, candesartan,
eprosartan and embusartan. J Hypertens, 19:2241–50.
Barone FC, Coatney RW, Chandra S, et al. 2001. Eprosartan reduces cardiac
hypertrophy, protects heart and kidney, and prevents early mortality
in severely hypertensive stroke-prone rats. Cardiovas Res, 50:
525–37.
Behr TM, Willette RN, Coatney RW, et al. 2004. Eprosartan improves
cardiac performance, reduces cardiac hypertrophy and mortality and
downregulates myocardial monocyte chemoattractant protein-1 and
inflammation in hypertensive heart disease. J Hypertens, 22:583–92.
Blankenberg S, Rupprecht HJ, Bickel C, et al. 2001. Circulating cell
adhesion molecules and death in patients with coronary artery disease.
Circulation, 104:1336–42.
Chobanian AV, Bakris GL, Black HR, et al. 2003. The Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. JAMA, 289:2560–72.
Collins R, Peto R, MacMahon S, et al. 1990. Blood pressure, stroke, and
coronary heart disease. Part 2, short-term reductions in blood pressure:
overview of randomised drug trials in their epidemiological context.
Lancet, 335:827–38.
Dahlöf B, Dvereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet,
359:995–1003.
De Gasparo M, Catt KJ, Inagami T, et al. 2000. International Union of
Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev,
52:415–72.
De Rosa G, Ragonesi PD, Mugellini A, et al. 2004. Effects of telmisartan
compared with eprosartan on blood pressure control, glucose
metabolism and lipid profile in hypertensive, type 2 diabetic patients:
a randomized, double-blind, placebo-controlled 12-month study.
Hypertens Res, 27:457–64.
Devereux RB, Wachtell K, Gerdts E, et al. 2004. Prognostic significance
of left ventricular mass change during treatment of hypertension.
JAMA, 292:2350–6.
Elliott WJ. 1999. Double-blind comparison of eprosartan and enalapril on
cough and blood pressure in unselected hypertensive patients. J Human
Hypertens, 13:413–17.
Fliser D, Buchholz K, Haller H. 2004. Antiinflammatory effects of
angiotensin II subtype 1 receptor blockade in hypertensive patients
with microinflammation. Circulation, 110:1103–7.
Fournier A, Messerli FH, Achard JM, et al. 2004. Cerebroprotection
mediated by angiotensin II: a hypothesis supported by recent
randomized clinical trials. J Am Coll Cardiol, 43:1343–7.Vascular Health and Risk Management 2006:2(1) 85
Eprosartan and organ protection
Garcia Puig J, Mateos F, Buño A, et al. 1999. Effect of eprosartan and
losartan on Eric acid metabolism in patients with essential
hypertension. J Hypertens, 17:1033–9.
[GC] Guidelines Committee. 2003. European Society of Hypertension-
European Society of Cardiology guidelines for the management of
arterial hypertension. J Hypertens, 21:1011–53.
Guimaraes S, Pinheiro H, Tavares P, et al. 2001. Differential effects of
eprosartan and losartan at prejunctional angiotensin II receptors.
Naunyn-Schmiedebergs Arch Pharmacol, 363:509–14.
Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive
patients at high cardiovascular risk treated with regimens based on
valsartan or amlodipine: the VALUE randomised trial. Lancet,
363:2022–31.
Kjeldsen SE, Julius S, Hedner T, et al. 2001. Stroke is more common than
myocardial infarction in hypertension: analysis based on 11 major
randomized intervention trials. Blood Pr, 10:190–2.
Klein IH, Ligtenberg G, Oey PL, et al. 2003. Enalapril and losartan reduce
sympathetic hyperactivity in patients with chronic renal failure. J Asm
Soc Nephrol, 14:425–30.
Koh KK, Ahn JY, Han SH, et al. 2003. Pleiotropic effects of angiotensin II
receptor blocker in hypertensive patients. J Am Coll Cardiol, 42:
905–10.
Labios M, Martinez M, Gabriel F, et al. 2004. Effect of eprosartan on
cytoplasmic free calcium mobilization, platelet activation, and
microparticle formation in hypertension. Am J Hypertens, 17:
757–63.
Leu HB, Charng MJ, Ding PY. 2004. A double blind randomized trial to
compare the effects of eprosartan and enalapril on blood pressure,
platelets, and endothelium function in patients with essential
hypertension. Jpn Heart J, 45:623–35.
Lewington S, Clarke R, Qizilbash N, et al; Prospective Studies
Collaboration. 2002. Age-specific relevance of usual blood pressure
to vascular mortality: a meta-analysis of individual data for one million
adults in 61 prospective studies. Lancet, 360:1903–13.
Li J, Culman J, Hortnagl H, et al. 2005. Angiotensin AT2 receptor protects
against cerebral ischemia-induced neuronal injury. FASEB J, 19:
617–19.
Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis.
Circulation, 105:1135–43.
Ligtenberg G, Blankestijn PJ, Oey PL, et al. 1999. Reduction of sympathetic
hyperactivity by enalapril in patients with chronic renal failure. N Engl
J Med, 340:1321–8.
Lithell H, Hansson L, Skoog I, et al. 2003. The Study on Cognition and
Prognosis in the Elderly (SCOPE): principal results of a randomized
double-blind intervention trial. J Hypertens, 21:875–88.
Makris TK, Stavroulakis G, Papadoppoulos DP, et al. 2004. Eprosartan
effect on fibrinolytic/hemostatic variables in arterial hypertension: a
comparative study to losartan. Drugs Exp Clin Res, 30:125–32.
Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist
prevents electrical remodeling in atrial fibrillation. Circulation,
101:2612–17.
Ohlstein EH, Brooks DP, Feuerstein GZ, et al. 1997. Inhibition of
sympathetic outflow by the angiotensin II receptor antagonist,
eprosartan, but not by losartan, valsartan or irbesartan: relationship to
differences in prejunctional angiotensin II receptor blockade.
Pharmacology, 55:244–51.
Okin PM, Devereux RB, Jern S, et al. 2004. Regression of electro-
cardiographic left ventricular hypertrophy during antihypertensive
treatment and the prediction of major cardiovascular events. JAMA,
292:2343–9.
Perticone F, Ceravolo R, Pujia A, et al. 2001. Prognostic significance of
endothelial dysfunction in hypertensive patients. Circulation, 104:
191–6.
Plosker GL, Foster RH. 2000. Eprosartan: a review of its use in the
management of hypertension. Drugs, 60:177–201.
[PROGRESS] PROGRESS Collaborative Group. 2001. Randomised trial
of a perindopril-based blood-pressure-lowering regimen among 6105
individuals with previous stroke or transient ischaemic attack. Lancet,
358:1033–41.
Rahman ST, Lauten WB, Khan QA, et al. 2002. Effects of eprosartan versus
hydrochlorothiazide on markers of vascular oxidation and
inflammation and blood pressure (renin-angiotensin system
antagonists, oxidation, and inflammation). Am J Cardiol, 89:686–90.
Robins GW, Scott LJ. 2005. Eprosartan. A review of its use in the
management of hypertension. Drugs, 65:2355–77.
Ruilope LM, Jager B, Prichard B. 2001. Eprosartan versus enalapril in
elderly patients with hypertension: a double-blind randomized trial.
Blood Pr, 10: 223–9.
Schächinger V, Britten M, Zeiher AM. 2000. Prognostic impact of coronary
vasodilator dysfunction on adverse long-term outcome of coronary
heart disease. Circulation, 101:1899–906.
Schiffrin EL, Park JB, Intengan HD, et al. 2000. Correction of arterial
structure and endothelial dysfunction in human essential hypertension
by the angiotensin receptor antagonist losartan. Circulation, 101:
1653–9.
Schrader J, Lüders S, Kulchewski A, et al. 2003. The ACCESS study.
Evaluation of acute candesartan cilexetil therapy in stroke survivors.
Stroke, 34:1699–703.
Schrader J, Lüders S, Kulschewski A, et al. 2005. Morbidity and mortality
after stroke, eprosartan compared with nitrendipine for secondary
prevention. Principal results of a prospective randomized controlled
study (MOSES). Stroke, 36:1218–26.
Sierra C, de la Sierra A. 2005. Antihypertensive, cardiovascular, and
pleiotropic effects of angiotensin-receptor blockers. Curr Opin Nephrol
Hypertens, 14:435–41.
Sega R. 1999. Efficacy and safety of eprosartan in severe hypertension.
Blood Pr, 8:114–21.
Staessen JA, Fagard R, Thijs L, et al. 1997. Randomised double-blind
comparison of placebo and active treatment for older patients with
isolated systolic hypertension. Lancet, 350:757–64.
Staessen JA, Gasowski J, Wang JG, et al. 2000. Risks of untreated and
treated isolated systolic hypertension in the elderly: meta-analysis of
outcome trials. Lancet, 355:865–72.
Struck J, Muck P, Trübger D, et al. 2002. Effects of selective angiotensin
II receptor blockade on sympathetic nerve activity in primary
hypertensive subjects. J Hypertens, 20:1143–9.
Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration.
2003. Effects of different blood-pressure-lowering regimens on major
cardiovascular events: results of prospectively-designed overviews of
randomised trials. Lancet, 362:1527–35.
Vasan RS, Beiser A, Seshadri S, et al. 2002. Residual lifetime risk for
developing hypertension in middle-aged women and men: The
Framingham Heart Study. JAMA, 287:1003–10.
Wachtell K, Lehto M, Gerdts E, et al. 2005. Angiotensin II receptor
blockade reduces new-onset atrial fibrillation and subsequent stroke
compared to atenolol: the Losartan Intervention For End Point
Reduction in Hypertension (LIFE) study. J Am Coll Cardiol, 45:
712–19.
Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic
hypertension in the elderly. Systolic Hypertension in China (Syst-
China) Collaborative Group. Arch Intern Med, 160:211–20.
Wolf-Maier K, Cooper RS, Banegas JR, et al. 2003. Hypertension
prevalence and blood pressure levels in 6 European countries, Canada,
and the United States. JAMA, 289:2363–9.